BioPharma Resources

Drug Trial Radar · NCT06324604

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jun 13, 2024

Primary completion

Mar 31, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.

Conditions

  • Healthy Volunteers
  • Type 1 Diabetes

Interventions

  • PlaceboDrug

    MTX-101

  • MTX-101Drug

    MTX-101 (bispecific CD8 Treg modulator)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of single, ascending dose levels of MTX-101Time frame: Enrollment to 8 weeks post dose
  2. Safety of multiple, ascending dose levels of MTX-101Time frame: Enrollment to 11 weeks following the last dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St Vincent's Hospital Melbourne (SVHM)

    Fitzroy, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • The Royal Melbourne Hospital

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.